NCT/Study#

NCT04421378 /

XPORT-GBM-029

A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for ACTIVEly Diagnosed or Recurrent Glioblastoma

A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for ACTIVEly Diagnosed or Recurrent Glioblastoma

DISEASE GROUP:
Neuro-Oncology
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: